TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06101420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily
Study: NCT05006248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional robotic continuous passive movement training
Description: The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
Study: NCT04937855

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05006248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic and Visual Feedback
Description: The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
Study: NCT04642976

Intervention type: DEVICE
Intervention: Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters
Description: Ganglionated plexi will be mapped using high frequency stimulation with standard ablation catheters attached to a Natus Cortical Stimulator for high frequency stimulation. Vagal innervation to the heart will be assessed with non-invasive Parasym tragal stimulation.
Study: NCT06288893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHEN211 Tablets
Description: SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SHEN211 Tablets
Description: Placebo tablets, participants will receive 3 tablets QD (once daily) on Day 1 and 1 tablet QD orally on Days 2-5
Study: NCT06434298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move
Description: As described under study arm description
Study: NCT04771312

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile app information-only intervention
Description: Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants can respond to daily questions in a diary. Participants can also use a locator tool to find where PrEP can be found near them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile app social support network intervention
Description: Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants are shown an online chatting tool where they can discuss with each other and answer daily questions. Participants can also use a locator tool to find where PrEP can be found near them.
Study: NCT04781504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session
Study: NCT04984200

Intervention type: PROCEDURE
Intervention: Retinal imaging
Description: Subjects will undergo retinal imaging before and/or after administration of mydriatic agent

Intervention type: DRUG
Intervention: Mydriatic Agent
Description: Subjects will be administered mydriatic medication to dilate their pupils.
Study: NCT05860985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZEISS disposable
Description: a comparison will be done between the present lenses used (reusable RESIGHT lenses and disposable Vitreq contact lens) and the new disposable RESIGHT lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZEISS disposable
Description: a comparison will be done between the present lenses used (reusable RESIGHT lenses and disposable Vitreq contact lens) and the new disposable RESIGHT lenses.
Study: NCT06068621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
Description: 1. Azacytidine (75 mg/m2/day, days 1 to 7).~2. Cytarabine (75-100 mg/m2 bid, days 1 to 5).~3. Aclacinomycin(20 mg/day, days 1,3,5).~4. Chidamide (30 mg/day , days 1,4,8,11).~5. Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~6. Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3+7
Description: IA regimen:~1. Idarubicin (8-10 mg/m2) for 3 days .~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~1. Daunorubicin(60 mg/m2) for 3 days.~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.
Study: NCT06429072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: • I-MASS begins with one introductory telephone call by a mindfulness coach within 1 week of the patient scheduling surgery to introduce the participant to the Pattern Health app, discuss the benefits of combining mindfulness and acupuncture, discuss how to access the Healthwise educational content, and lead a brief (\~10 min) mindfulness exercise, as desired. Thereafter, participants will complete 4 self-directed mindfulness modules through the Pattern Health app (1 prior to surgery, 3 following surgery). Each mindfulness module is anticipated to last one week and includes a short (4-5 min) introductory video, daily sessions comprised of a 6-8 min guided mediation, and interactive suggestions for how to apply mindfulness within a daily routine (\~10-12 min total per daily session).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: This arm also includes up to 8 total acupuncture treatments (1 prior to surgery and up to 7 treatments in the 12 weeks after surgery). Auricular acupuncture will be the preferred form of acupuncture used. This technique involves inserting tiny needles in specific areas of the outer ear to target points believed to influence pain. If participants are unable to tolerate auricular acupuncture, they will have the option to receive peripheral acupuncture.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced education
Description: • The program consists of education prior to and after surgery for all participants. All of the educational material is delivered via the Pattern Health App. All educational content is from the Healthwise.net Duke Health Library (https://www.healthwise.net/dukehealth/Content) and is carefully selected with input by surgeons to be delivered during the appropriate phase of recovery. Education is in the form of short reading materials or videos, all designed to help safely and effectively recover from surgery. Educational topics include learning how to lift and sit when experiencing pain, proper precautions following surgery, how to ease back into daily activities following surgery, and ways to self-manage pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced education
Description: • The program consists of education prior to and after surgery for all participants. All of the educational material is delivered via the Pattern Health App. All educational content is from the Healthwise.net Duke Health Library (https://www.healthwise.net/dukehealth/Content) and is carefully selected with input by surgeons to be delivered during the appropriate phase of recovery. Education is in the form of short reading materials or videos, all designed to help safely and effectively recover from surgery. Educational topics include learning how to lift and sit when experiencing pain, proper precautions following surgery, how to ease back into daily activities following surgery, and ways to self-manage pain.
Study: NCT05321602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010 156 mg treatment group, deltoid
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010 156 mg treatment group, gluteal
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010 351 mg treatment group, deltoid
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010 351 mg treatment group, gluteal
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Study: NCT05665283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ensartinib Hydrochloride
Description: oral ALK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ensartinib Hydrochloride
Description: oral ALK inhibitor
Study: NCT05809700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freshly manufactured 35 kDa hyaluronan fragment
Description: This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.
Study: NCT05272605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)
Description: Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)
Description: Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)
Description: Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 beta variant RBD mRNA vaccine
Description: Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 beta variant RBD mRNA vaccine
Description: Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 beta variant RBD mRNA vaccine
Description: Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo comparator
Study: NCT05600751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiosurgery of ganglion stellatum
Description: Patients will undergo radiosurgery of ganglion stellatum (left one or both)
Study: NCT05600517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
Study: NCT01738412

Intervention type: DEVICE
Intervention: Neurokeeper stroke detector
Description: Monitoring stroke patients
Study: NCT06308211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOTOR IMAGERY+MIRROR THERAPY+ROUTINE PHYSICAL THERAPY
Description: Subjects will be instructed to watch the video provided and recorded by investigator.In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.Participants will be than instructed to carry out the task in verbal commands given whenever necessary.The unaffected limb will be placed in front of the mirror so that the reflected illusion of the limb would be hallucinated to represent the affected limb and routine physical therapy includes passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOTOR RELEARNING PROGRAM+ROUTINE PHYSICAL THERAPY
Description: Motor relearning consists of five components including analysis of task, practice of missing components, practice of task and transference of training. Patient will be asked to practice task in both sitting and standing~* supine to side-lying to sitting~* looking up at ceiling (ensure that centre of body mass does not move back when head is tilted back)~* without moving one's feet, turning to gaze over each other's shoulders and scanning the surroundings for specific items, reaching motions in multiple directions while moving the head and trunk, scooting in bed, altering the base of support (standing with your feet together, in tandem, with one foot on a step, or on one leg)~* squatting to pick up an object and cross over stepping and routine physical therapy includes Passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions).
Study: NCT06309628

Intervention type: DIAGNOSTIC_TEST
Intervention: Breathe sample
Description: Patients will provide two breathe sample into the Breathe device to see if their VOC patterns can be used to diagnose lung transplant rejection.
Study: NCT06638359

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: moderate exercise
Description: moderate exercise for 47 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate exercise
Description: moderate exercise for 47 minutes

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: interval exercise
Description: interval exercise for 28 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interval exercise
Description: interval exercise for 28 minutes

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control (placebo) group
Description: without exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control (placebo) group
Description: without exercise
Study: NCT06638931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: The intervention consists of administering Nivolumab 480 mg intravenously every 4 weeks, with a +5 day window for postponement but not for advancement of treatment. Treatment will continue until limiting toxicity, disease progression, or for a maximum period of 12 months (13 cycles) as maintenance therapy, provided the patient maintains stable disease, a partial response, or a complete response. Patients who are off treatment for more than 56 days (2 cycles) due to Nivolumab-related toxicities or other clinical issues will be discontinued from the protocol.~After 12 months of treatment or in the event of study discontinuation for any reason, patients will be followed by the research team via telephone every 60 days, with a +/- 7 day window, until death.
Study: NCT06640673

Intervention type: DIAGNOSTIC_TEST
Intervention: Hd-EEG
Description: Subjects undergo a clinical and neuropsychological assesment, then a Hd-EEG both during resting state and execution of tasks, and structural Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Hd-EEG
Description: Subjects undergo a clinical and neuropsychological assesment, then a Hd-EEG both during resting state and execution of tasks, and structural Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Hd-EEG
Description: Subjects undergo a clinical and neuropsychological assesment, then a Hd-EEG both during resting state and execution of tasks, and structural Magnetic Resonance Imaging
Study: NCT05236023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero separation and couplet care
Description: The essence of the intervention is that treatment-requiring mother-infant dyads are admitted together and receives couplet care provided by neonatal nurses.~The nurses will be educated for the intervention by participating in a two-day course about postpartum observations, treatment and care; and participate in education about family-centred care and family-focused nursing.
Study: NCT05148338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive risk factor treatment
Description: 1. Apnea screening with Home Sleep Apnea Test. Referral to sleep physician if apnea-hypopnea index (AHI) is greater than 5~2. Weight management counseling by dietician if body mass index (BMI) is above 27 kg/m2~3. Physical activity program under supervision of physiotherapist at a specialized cardiac rehabilitation centre if BMI is over 27 or if there are complaints during exercise~4. Smoking cessation at specialized outpatient clinic~5. Blood pressure control, lipid management, glycaemic control, alcohol intake reduction by specialized AF nurse~6. Motivation and education through a digital health platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard usual care: Treatment by cardiologist conform existing guidelines
Study: NCT06126172

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparametric magnetic resonance imaging (mpMRI)
Description: Detecting and localizing prostate cancers and using radiomics extracted from prostate mpMRI for risk stratification patients of histological aggressiveness as well as to predict very early recurrence of PCA patients within 6 months after radical prostatectomy.
Study: NCT06637293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeepECG plateform diagnosis & recommendations
Description: EchoNeXT\& ECG-AI algorithm
Study: NCT06170892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo method
Description: The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.
Study: NCT05859685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Manual therapy techniques:~* Talar dorsal sliding technique. Dorsal mobilization of the talus, with the patient in the supine position and ankle dorsiflexion, without pain or discomfort. The physiotherapist will exercise an anteroposterior mobilization of the talus, with a dorsal glide~* Mulligan movement mobilization technique: The patient will be in a standing position, with the ankle to be treated forward. You will be given an aid or support in the upper extremity to maintain stability.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and times of administration will be the same